Antibodies specific for human CD22 and their therapeutic and digagnostic uses

Details for Australian Patent Application No. 2003223007 (hide)

International Classifications

Event Publications

7 August 2003 Complete Application Filed

Priority application(s): 0210121.0 02.05.02 GB

8 January 2004 Application Open to Public Inspection

Published as AU-B-2003223007

6 March 2008 Assignment before Grant

Celltech R&D Limited The application has been assigned to UCB Pharma S.A.

16 July 2009 Application Accepted

Published as AU-B-2003223007

30 July 2009 Application for Amendment

The nature of the amendment is: Amend the invention title to read Antibodies specific for human CD22 and their therapeutic and diagnostic uses. Address for service in Australia - Freehills Patent & Trade Mark Attorneys Level 43 101 Collins Street Mebourne VIC 3000

15 October 2009 Application for Amendment

The nature of the amendment is as shown in the statement(s) filed 10 Sep 2009. Address for service in Australia - Freehills Patent & Trade Mark Attorneys Level 43 101 Collins Street Mebourne VIC 3000

3 December 2009 Amendment Made

The nature of the amendment is: Amend the invention title to read Antibodies specific for human CD22 and their therapeutic and diagnostic uses

11 February 2010 Amendment Made

The nature of the amendment is as shown in the statement(s) filed 10 Sep 2009

11 February 2010 Standard Patent Sealed

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.